

Exhibit 90

United States of America ex rel. Ven-a-Care of the Florida Keys, Inc. v. Boehringer Ingelheim Corp. et al.

Civil Action No. 07-10248-PBS

Exhibit to the July 24, 2009, Declaration of James J. Fauci
In Support of Plaintiff's Motion for Partial Summary Judgment and
In Opposition to the Roxane Defendants' Motion For Partial Summary Judgment

ORAMORPH - SR

RLI-TX_66528

RLI-AWP-00165405

ROX038-6851 FL

GRAMORPH SR

RLI-TX_66529

RLI-AWP-00165406

ROX038-6852 FL

To: AM's & RD's

From: Craig Russell

Date: January 11, 1999

RE: Oramorph SR Price Increase

CC: Ellexson, Feldman, Hart, Lewis, Mayhew, Shaffer, and D. Smith

Roxane Laboratories, Inc., has increased the prices of Oramorph SR on Wholesale Acquisition Cost (WAC), Average Wholesale Price (AWP) and Direct Price, effective January 11, 1999. The price changes effect all strengths and package sizes.

Attached you will find a table outlining the changes and an additional table outlining how the price changes compare to the prices of competitive products.